Radiotracers that target cardiac sympathetic activity, such as the norepinephrine analogue, iodine-123-meta-iodobenzylguanidine (mIBG), may provide insight into the presence and distribution of sympathetic nerve terminals in the left ventricular myocardium in relation to regional wall motion abnormalities in the acute, subacute, and recovery phases of the takotsubo syndrome. The mIBG images may be supplemented with myocardial perfusion and metabolic imaging studies to garner information on myocardial ischemia, infarction, and metabolic stunning (3, 4) .
In this issue of iJACC, Christensen et al. (5) report on a study that prospectively evaluated cardiac sympathetic activity by mIBG scan and blood catecholamine levels in 32 patients with takotsubo cardiomyopathy and 20 control subjects in subacute (6 to 10 days after presentation with acute coronary syndrome) and recovery phases (4 months later).
The study was designed such that the "disease This finding provides credence to the concept that exaggerated sympathetic activation with elevated plasma catecholamines plays a pivotal role in the pathophysiology of takotsubo cardiomyopathy.
However, the mIBG scan was performed at the subacute phase, not before or at the onset of the disease.
Consequently, whether cardiac sympathetic disturbance is the primary cause and trigger of Takotsubo cardiomyopathy or simply a compensatory response to heart failure cannot be differentiated with the current data. 
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